Defunct Company
Total Trials
27
As Lead Sponsor
24
As Collaborator
3
Total Enrollment
12,096
NCT00375609
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Phase: Phase 2
Role: Lead Sponsor
Start: May 31, 2006
Completion: Feb 28, 2007
NCT01765855
An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects
Phase: Phase 1
Start: Sep 30, 2007
Completion: Oct 31, 2007
NCT01765868
A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers
NCT00546260
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Start: Nov 30, 2007
Completion: Jul 31, 2008
NCT00742859
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Start: Oct 31, 2008
Completion: Nov 30, 2009
NCT00751231
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
Start: Dec 31, 2008
Completion: Apr 30, 2010
NCT00999336
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
Start: Jul 31, 2009
Completion: Feb 28, 2010
NCT00984113
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
Start: Sep 30, 2009
Completion: Dec 31, 2009
NCT01229254
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
Start: Sep 30, 2010
Completion: Apr 30, 2011
NCT01583218
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Phase: Phase 3
Start: Mar 31, 2012
Completion: Jan 31, 2016
NCT03218241
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
Start: Jun 30, 2012
Completion: Oct 31, 2012
NCT01758432
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
Start: Dec 31, 2012
Completion: Sep 30, 2015
NCT03551730
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
NCT03551743
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)
NCT03578146
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
NCT01994382
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Phase: Phase 1/2
Role: Collaborator
Start: Aug 30, 2013
Completion: Dec 15, 2020
NCT02207725
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
Start: Mar 31, 2014
NCT02220725
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
Start: May 31, 2014
Completion: Aug 31, 2015
NCT03330457
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
Start: Aug 6, 2015
Completion: Feb 22, 2016
NCT02596100
A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations
Start: Sep 30, 2015
Completion: Nov 30, 2015
NCT02745054
Safety of Oral Anticoagulants Registry
Phase: N/A
Start: Aug 31, 2016
Completion: Oct 31, 2018
NCT03083704
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
Start: Feb 26, 2017
Completion: Sep 28, 2017
NCT03310021
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
Start: Aug 28, 2017
Completion: Aug 13, 2019
NCT03397888
The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
Start: Nov 16, 2017
Completion: Jan 16, 2018
NCT03613402
BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Start: Sep 30, 2018
Completion: Jan 31, 2020
NCT03728166
Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)
Start: Feb 1, 2019
Completion: Dec 31, 2024
NCT04021082
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Phase: Phase 2/3
Start: Nov 15, 2019
Completion: Jun 1, 2023